Patents - Global Data - Dimensions
Patent-family-89073083
Applicants:
- Genmab (Denmark) [NORA names: Genmab; Private Research; Denmark; Europe, EU; Nordic; OECD]
- BioNTech (Germany) [NORA names: Germany; Europe, EU; OECD]
Abstract
The present invention relates to combination therapy using a binding agent that binds to human CD40 and to human CD137 in combination with a checkpoint inhibitor which is an inhibitor of the PD-1/PD- L1 axis (in particular pembrolizumab) and chemotherapy to reduce or prevent progression of head and neck squamous cell carcinoma (HNSCC) or treat HNSCC.
Patent Family Records (1)
MULTISPECIFIC ANTIBODY AGAINST CD40 AND CD137 IN COMBINATION THERAPY WITH ANTI-PD1 AB AND CHEMOTHERAPY
BioNTech (Germany), BioNTech SE, GENMAB AS, Genmab (Denmark) SAHIN UGUR, NIEWOOD MICHELLE, ADAMS III HOMER, (...more)
2024, WO-2024115725-A1
